JP2017533250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533250A5 JP2017533250A5 JP2017525079A JP2017525079A JP2017533250A5 JP 2017533250 A5 JP2017533250 A5 JP 2017533250A5 JP 2017525079 A JP2017525079 A JP 2017525079A JP 2017525079 A JP2017525079 A JP 2017525079A JP 2017533250 A5 JP2017533250 A5 JP 2017533250A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- carbocyclyl
- optionally substituted
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1cc(C(Cl=*)=CN(*)C2=O)c2[n]1 Chemical compound *c1cc(C(Cl=*)=CN(*)C2=O)c2[n]1 0.000 description 34
- UQUHZULWYMQRSS-SNAWJCMRSA-N C/C=C/CN(C=C(C(N(CC1)CCC1N(C)C)=O)c1c2[nH]cc1)C2=O Chemical compound C/C=C/CN(C=C(C(N(CC1)CCC1N(C)C)=O)c1c2[nH]cc1)C2=O UQUHZULWYMQRSS-SNAWJCMRSA-N 0.000 description 1
- LUCLJGBDSYDVPO-UHFFFAOYSA-N C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O Chemical compound C/S=C/C(N(CC1)CCC1C1=CC(F)=CC#CC1)=O LUCLJGBDSYDVPO-UHFFFAOYSA-N 0.000 description 1
- YYJHYDDYSZUMOR-UHFFFAOYSA-N CC(C)c(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(C)c(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O YYJHYDDYSZUMOR-UHFFFAOYSA-N 0.000 description 1
- HDZPZWTWOZYVDA-UHFFFAOYSA-N CC(C)c1cccc(N(CC2)CCC2N(C)C(C2=CN(C)C(C)c3c2cc[nH]3)=O)c1 Chemical compound CC(C)c1cccc(N(CC2)CCC2N(C)C(C2=CN(C)C(C)c3c2cc[nH]3)=O)c1 HDZPZWTWOZYVDA-UHFFFAOYSA-N 0.000 description 1
- LEMGAKAAUNGWHX-UHFFFAOYSA-N CC(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O LEMGAKAAUNGWHX-UHFFFAOYSA-N 0.000 description 1
- RFLTUNKOJLSFRI-UHFFFAOYSA-N CC(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O RFLTUNKOJLSFRI-UHFFFAOYSA-N 0.000 description 1
- HMCFXEKTKFEKCT-UHFFFAOYSA-N CC(CCC1)CN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CC(CCC1)CN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O HMCFXEKTKFEKCT-UHFFFAOYSA-N 0.000 description 1
- HSXOJHXRNKVLHL-VURMDHGXSA-N CC(CN(CC1)C(C(C(/C=C\N)=C2C)=CN(C)C2=O)=O)C1N(C)C Chemical compound CC(CN(CC1)C(C(C(/C=C\N)=C2C)=CN(C)C2=O)=O)C1N(C)C HSXOJHXRNKVLHL-VURMDHGXSA-N 0.000 description 1
- VWVDYFBWPFYGNZ-UHFFFAOYSA-N CC(CN(CC1)CCC1NC)c1ccccc1 Chemical compound CC(CN(CC1)CCC1NC)c1ccccc1 VWVDYFBWPFYGNZ-UHFFFAOYSA-N 0.000 description 1
- JAKDWKVKEBOKAO-UHFFFAOYSA-N CC(N(CC1)CCC1C1=NCCC=C1)=O Chemical compound CC(N(CC1)CCC1C1=NCCC=C1)=O JAKDWKVKEBOKAO-UHFFFAOYSA-N 0.000 description 1
- ADKJRMANIGACDE-UHFFFAOYSA-N CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O Chemical compound CC(N(CC1)CCC1[n]1c(cccc2)c2nc1)=O ADKJRMANIGACDE-UHFFFAOYSA-N 0.000 description 1
- GWFPELGLVGDRGE-UHFFFAOYSA-N CCCC(N(CC1)CC=C1c1nccnc1)=O Chemical compound CCCC(N(CC1)CC=C1c1nccnc1)=O GWFPELGLVGDRGE-UHFFFAOYSA-N 0.000 description 1
- UGJCAXHVKZMJJA-UHFFFAOYSA-N CCN(CC)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CCN(CC)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O UGJCAXHVKZMJJA-UHFFFAOYSA-N 0.000 description 1
- FBVGIYYPPOCZOL-UHFFFAOYSA-N CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O Chemical compound CCS(C)C(N(C)CC1CCN(CC2COCCC2)CC1)=O FBVGIYYPPOCZOL-UHFFFAOYSA-N 0.000 description 1
- ZEXPBEBJNWJYOD-UHFFFAOYSA-N CCc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CCc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O ZEXPBEBJNWJYOD-UHFFFAOYSA-N 0.000 description 1
- BXDBCNHTWWMPOP-UHFFFAOYSA-N CCc1cccc(N(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)c1 Chemical compound CCc1cccc(N(CC2)CCC2N(C)C(C(C2C=CNC22)=CN(C)C2=O)=O)c1 BXDBCNHTWWMPOP-UHFFFAOYSA-N 0.000 description 1
- JZSMQBUKLWKLAH-UHFFFAOYSA-N CN(C(CC1)CCN1c1nc(C#N)ncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2O)=O Chemical compound CN(C(CC1)CCN1c1nc(C#N)ncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2O)=O JZSMQBUKLWKLAH-UHFFFAOYSA-N 0.000 description 1
- MKBQGEGVONDJOL-UHFFFAOYSA-N CN(C(CC1)CCN1c1nc(C(F)(F)F)ccn1)C(C(C1C=CNC11)=CN(CC=C)C1O)=O Chemical compound CN(C(CC1)CCN1c1nc(C(F)(F)F)ccn1)C(C(C1C=CNC11)=CN(CC=C)C1O)=O MKBQGEGVONDJOL-UHFFFAOYSA-N 0.000 description 1
- HPNQBNLYZZQXKT-UHFFFAOYSA-N CN(C(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O Chemical compound CN(C(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(CC=C)C2=O)=O HPNQBNLYZZQXKT-UHFFFAOYSA-N 0.000 description 1
- BKNNKEDBPTYNGM-UHFFFAOYSA-N CN(C)C(C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=O Chemical compound CN(C)C(C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O)=O BKNNKEDBPTYNGM-UHFFFAOYSA-N 0.000 description 1
- CFXSNMNOGBSDGU-UHFFFAOYSA-N CN(C)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(CCC1CC1)C2=O)=O Chemical compound CN(C)C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(CCC1CC1)C2=O)=O CFXSNMNOGBSDGU-UHFFFAOYSA-N 0.000 description 1
- RHTIIFADKOEUSR-UHFFFAOYSA-N CN(C)C(N(CC1)CCC1c1ncncc1)=O Chemical compound CN(C)C(N(CC1)CCC1c1ncncc1)=O RHTIIFADKOEUSR-UHFFFAOYSA-N 0.000 description 1
- BWDUSWMVCCCWOD-UHFFFAOYSA-N CN(C1CCCCC1)C(CC1)CCN1C=O Chemical compound CN(C1CCCCC1)C(CC1)CCN1C=O BWDUSWMVCCCWOD-UHFFFAOYSA-N 0.000 description 1
- IYIIMQCNUYRHBO-UHFFFAOYSA-N CN(C1O)C=C(C2OC2N(CC2)CCC2N2CCOCC2)c2c1[nH]cc2 Chemical compound CN(C1O)C=C(C2OC2N(CC2)CCC2N2CCOCC2)c2c1[nH]cc2 IYIIMQCNUYRHBO-UHFFFAOYSA-N 0.000 description 1
- RNYPMKBFHRSMPM-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1C#N)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1C#N)=O)c1c2[nH]cc1)C2=O RNYPMKBFHRSMPM-UHFFFAOYSA-N 0.000 description 1
- BXQUMVORFIOMJP-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1C(F)(F)F)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1C(F)(F)F)=O)c1c2[nH]cc1)C2=O BXQUMVORFIOMJP-UHFFFAOYSA-N 0.000 description 1
- KFFRKYMJDNFLSJ-UHFFFAOYSA-N CN(C=C(C(N(CC1)CCC1OC)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N(CC1)CCC1OC)=O)c1c2[nH]cc1)C2=O KFFRKYMJDNFLSJ-UHFFFAOYSA-N 0.000 description 1
- MOVIQYNEXLEQEM-UHFFFAOYSA-N CN(C=C(C(N1CCC(CC2N=CC=CC2)CC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CC2N=CC=CC2)CC1)=O)c1c2[nH]cc1)C2=O MOVIQYNEXLEQEM-UHFFFAOYSA-N 0.000 description 1
- SVPKPAOXAZWQPH-UHFFFAOYSA-N CN(C=C(C(N1CCC(CCc2ccncc2)CC1)O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CCc2ccncc2)CC1)O)c1c2[nH]cc1)C2=O SVPKPAOXAZWQPH-UHFFFAOYSA-N 0.000 description 1
- NQUSIPINLCHYRE-UHFFFAOYSA-N CN(C=C(C(N1CCC(CO)CC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCC(CO)CC1)=O)c1c2[nH]cc1)C2=O NQUSIPINLCHYRE-UHFFFAOYSA-N 0.000 description 1
- FUDSXSIRXAOABP-UHFFFAOYSA-N CN(C=C(C(N1CCCCC1)=O)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C(N1CCCCC1)=O)c1c2[nH]cc1)C2=O FUDSXSIRXAOABP-UHFFFAOYSA-N 0.000 description 1
- VZDGRRGLSFQPCC-UHFFFAOYSA-N CN(C=C(C1OC1N(CC1)CCC1c1ccccc1)c1c2[nH]cc1)C2=O Chemical compound CN(C=C(C1OC1N(CC1)CCC1c1ccccc1)c1c2[nH]cc1)C2=O VZDGRRGLSFQPCC-UHFFFAOYSA-N 0.000 description 1
- DOJJCJLLNUPQSU-UHFFFAOYSA-N CN(CC(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(CC(CC1)CCN1c1ncncc1)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O DOJJCJLLNUPQSU-UHFFFAOYSA-N 0.000 description 1
- OSOZVNXWKSZTGJ-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound CN(CC1)CCN1C(CC1)CCN1C(C(c1c2[nH]cc1)=CN(C)C2=O)=O OSOZVNXWKSZTGJ-UHFFFAOYSA-N 0.000 description 1
- TYWQMEBQIZLNKW-UHFFFAOYSA-N Cc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O Chemical compound Cc(cc1)ccc1N(CC1)CCC1N(C)C(C(c1c2[nH]cc1)=CN(C)C2=O)=O TYWQMEBQIZLNKW-UHFFFAOYSA-N 0.000 description 1
- TYELAZUJANXRHV-UHFFFAOYSA-N Cc1cc(NC(C(CN(C)C2=O)c3c2[nH]cc3)=O)ccc1 Chemical compound Cc1cc(NC(C(CN(C)C2=O)c3c2[nH]cc3)=O)ccc1 TYELAZUJANXRHV-UHFFFAOYSA-N 0.000 description 1
- INBAALZXDRSEDW-UHFFFAOYSA-N Cc1ccccc1CN1CCC(CN(C)C=O)CC1 Chemical compound Cc1ccccc1CN1CCC(CN(C)C=O)CC1 INBAALZXDRSEDW-UHFFFAOYSA-N 0.000 description 1
- FHXKOHRPZOJNSQ-UHFFFAOYSA-N O=CN(CC1)CCC1c(cc1)ccc1Cl Chemical compound O=CN(CC1)CCC1c(cc1)ccc1Cl FHXKOHRPZOJNSQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077711P | 2014-11-10 | 2014-11-10 | |
| US62/077,711 | 2014-11-10 | ||
| PCT/US2015/059997 WO2016077375A1 (en) | 2014-11-10 | 2015-11-10 | Bromodomain inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533250A JP2017533250A (ja) | 2017-11-09 |
| JP2017533250A5 true JP2017533250A5 (enExample) | 2018-12-20 |
| JP6639497B2 JP6639497B2 (ja) | 2020-02-05 |
Family
ID=54705827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525079A Expired - Fee Related JP6639497B2 (ja) | 2014-11-10 | 2015-11-10 | ブロモドメインインヒビターおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10258603B2 (enExample) |
| EP (1) | EP3218376B1 (enExample) |
| JP (1) | JP6639497B2 (enExample) |
| CN (1) | CN107108613B (enExample) |
| WO (1) | WO2016077375A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6535007B2 (ja) | 2013-12-20 | 2019-06-26 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規ピペリジンカルボキサミド化合物、その調製方法及び使用 |
| EP3218376B1 (en) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40943A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| EP3892272B1 (en) | 2016-04-22 | 2024-07-24 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| CN110198941B (zh) * | 2017-01-25 | 2021-09-28 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
| WO2019201291A1 (zh) * | 2018-04-20 | 2019-10-24 | 中国科学院上海药物研究所 | 组蛋白乙酰转移酶(hat)抑制剂及其用途 |
| MX2021000881A (es) * | 2018-07-24 | 2021-06-08 | Epizyme Inc | Compuestos de piridin-2-ona utiles como antagonistas de smarca2. |
| WO2020254565A1 (en) * | 2019-06-21 | 2020-12-24 | F. Hoffmann-La Roche Ag | Egfr inhibitors for the treatment of cancer |
| US11171132B2 (en) * | 2019-10-03 | 2021-11-09 | Globalfoundries U.S. Inc. | Bi-directional breakdown silicon controlled rectifiers |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| IL295709A (en) | 2020-03-05 | 2022-10-01 | C4 Therapeutics Inc | Compounds for targeted degradation of brd9 |
| WO2022051565A1 (en) * | 2020-09-04 | 2022-03-10 | Ikena Oncology, Inc. | Substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds and their use in treating medical conditions |
| CN117377668A (zh) * | 2020-10-15 | 2024-01-09 | 迈欧伏特治疗公司 | Pgdh抑制剂的吸入制剂及其使用方法 |
| TW202237095A (zh) | 2020-12-03 | 2022-10-01 | 德商艾斯巴赫生物有限公司 | Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性 |
| JP2024542045A (ja) * | 2021-11-03 | 2024-11-13 | バイン セラピューティクス インコーポレイテッド | 汎ｂｅｔ阻害剤の使用 |
| CN119365198A (zh) | 2022-05-02 | 2025-01-24 | 艾斯巴赫生物有限公司 | ALC1抑制剂的用途和与PARPi的协同作用 |
| JP2025525347A (ja) | 2022-06-16 | 2025-08-05 | アンフィスタ セラピューティクス リミテッド | 標的タンパク質分解のための新規の二官能性分子 |
| CA3267147A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | COMPOUNDS FOR THE TARGETED DEGRADATION OF A PROTEIN |
| GB202300833D0 (en) * | 2023-01-19 | 2023-03-08 | Nrg Therapeutics Ltd | Novel compounds |
| TW202523312A (zh) * | 2023-10-16 | 2025-06-16 | 美商克洛諾斯生技有限公司 | 離胺酸乙醯基轉移酶抑制劑 |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
| US12624035B2 (en) | 2024-09-06 | 2026-05-12 | Amphista Therapeutics Limited | Compounds for targeted protein degradation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| EP1953147A1 (en) | 2005-11-21 | 2008-08-06 | Japan Tobacco, Inc. | Heterocyclic compound and medicinal application thereof |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2014125408A2 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| EP2970285B1 (en) * | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| CN105026403B (zh) | 2013-03-12 | 2018-05-18 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| JP6386035B2 (ja) | 2013-06-12 | 2018-09-05 | ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド | 金属酵素阻害剤化合物 |
| PE20160540A1 (es) | 2013-06-28 | 2016-06-11 | Abbvie Inc | Inhibidores de bromodominios |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| MY180775A (en) | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| CN107108512B (zh) * | 2014-10-10 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| EP3218376B1 (en) | 2014-11-10 | 2019-12-25 | Genentech, Inc. | Bromodomain inhibitors and uses thereof |
| MA40943A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016086200A1 (en) | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| HK1245677A1 (zh) | 2015-01-23 | 2018-08-31 | Aclaris Therapeutics, Inc. | 用於治疗炎症和癌症的杂环itk抑制剂 |
| JP6709792B2 (ja) | 2015-01-29 | 2020-06-17 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
-
2015
- 2015-11-10 EP EP15801563.6A patent/EP3218376B1/en active Active
- 2015-11-10 WO PCT/US2015/059997 patent/WO2016077375A1/en not_active Ceased
- 2015-11-10 CN CN201580072351.6A patent/CN107108613B/zh not_active Expired - Fee Related
- 2015-11-10 JP JP2017525079A patent/JP6639497B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-10 US US15/592,012 patent/US10258603B2/en active Active